**Background of RASA3 Antibody**
RASA3 (RAS p21 protein activator 3), also known as GAP1m or R-RasGAP, is a member of the GTPase-activating protein (GAP) family that negatively regulates RAS signaling pathways. By accelerating the hydrolysis of GTP-bound RAS proteins to their inactive GDP-bound state, RASA3 acts as a critical modulator of cellular processes, including proliferation, differentiation, and apoptosis. It is particularly important in vascular development, platelet function, and immune cell regulation, with studies linking RASA3 dysfunction to pathological conditions like cancer, cardiovascular diseases, and bleeding disorders.
Antibodies targeting RASA3 are essential tools for studying its expression, localization, and role in signaling cascades. They enable researchers to detect RASA3 in techniques such as Western blotting, immunohistochemistry, and flow cytometry. Commercial RASA3 antibodies are typically developed against specific epitopes (e.g., N-terminal or C-terminal regions) and validated for applications across human, mouse, or rat models. However, due to potential cross-reactivity with homologous proteins, rigorous validation is required to ensure specificity.
Current research utilizes RASA3 antibodies to explore its involvement in tumor suppression, angiogenesis, and platelet activation, offering insights into therapeutic targets for diseases driven by RAS pathway dysregulation.